240 related articles for article (PubMed ID: 27050866)
21. Controlled drug release to the inner ear: Concepts, materials, mechanisms, and performance.
Mäder K; Lehner E; Liebau A; Plontke SK
Hear Res; 2018 Oct; 368():49-66. PubMed ID: 29576310
[TBL] [Abstract][Full Text] [Related]
22. The role of intracochlear drug delivery devices in the management of inner ear disease.
Ayoob AM; Borenstein JT
Expert Opin Drug Deliv; 2015 Mar; 12(3):465-79. PubMed ID: 25347140
[TBL] [Abstract][Full Text] [Related]
23. Inner ear drug delivery for auditory applications.
Swan EE; Mescher MJ; Sewell WF; Tao SL; Borenstein JT
Adv Drug Deliv Rev; 2008 Dec; 60(15):1583-99. PubMed ID: 18848590
[TBL] [Abstract][Full Text] [Related]
24. Effects of a dexamethasone-releasing implant on cochleae: A functional, morphological and pharmacokinetic study.
Liu Y; Jolly C; Braun S; Janssen T; Scherer E; Steinhoff J; Ebenhoch H; Lohner A; Stark T; Kiefer J
Hear Res; 2015 Sep; 327():89-101. PubMed ID: 25987502
[TBL] [Abstract][Full Text] [Related]
25. Disposition of nanoparticle-based delivery system via inner ear administration.
Chen G; Zhang X; Yang F; Mu L
Curr Drug Metab; 2010 Dec; 11(10):886-97. PubMed ID: 21208174
[TBL] [Abstract][Full Text] [Related]
26. Long term behavior of dexamethasone-loaded cochlear implants: In vitro & in vivo.
Rongthong T; Qnouch A; Gehrke MM; Danede F; Willart JF; de Oliveira PFM; Paccou L; Tourrel G; Stahl P; Verin J; Toulemonde P; Vincent C; Siepmann F; Siepmann J
Int J Pharm X; 2022 Dec; 4():100141. PubMed ID: 36465275
[TBL] [Abstract][Full Text] [Related]
27. Inner ear delivery of dexamethasone using injectable silk-polyethylene glycol (PEG) hydrogel.
Yu D; Sun C; Zheng Z; Wang X; Chen D; Wu H; Wang X; Shi F
Int J Pharm; 2016 Apr; 503(1-2):229-37. PubMed ID: 26972377
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evaluation of a hydrogel reservoir as a continuous drug delivery system for inner ear treatment.
Hütten M; Dhanasingh A; Hessler R; Stöver T; Esser KH; Möller M; Lenarz T; Jolly C; Groll J; Scheper V
PLoS One; 2014; 9(8):e104564. PubMed ID: 25105670
[TBL] [Abstract][Full Text] [Related]
29. Development of a microfluidics-based intracochlear drug delivery device.
Sewell WF; Borenstein JT; Chen Z; Fiering J; Handzel O; Holmboe M; Kim ES; Kujawa SG; McKenna MJ; Mescher MM; Murphy B; Swan EE; Peppi M; Tao S
Audiol Neurootol; 2009; 14(6):411-22. PubMed ID: 19923811
[TBL] [Abstract][Full Text] [Related]
30. A novel chitosan-hydrogel-based nanoparticle delivery system for local inner ear application.
Lajud SA; Nagda DA; Qiao P; Tanaka N; Civantos A; Gu R; Cheng Z; Tsourkas A; O'Malley BW; Li D
Otol Neurotol; 2015 Feb; 36(2):341-7. PubMed ID: 25587675
[TBL] [Abstract][Full Text] [Related]
31. Silk-coated dexamethasone non-spherical microcrystals for local drug delivery to inner ear.
Li M; Ai M; Yang Y; Yao X; Zhou Z; Wang H; Li C; Xu K
Eur J Pharm Sci; 2020 Jul; 150():105336. PubMed ID: 32360767
[TBL] [Abstract][Full Text] [Related]
32. A regulated delivery system for inner ear drug application.
Lajud SA; Han Z; Chi FL; Gu R; Nagda DA; Bezpalko O; Sanyal S; Bur A; Han Z; O'Malley BW; Li D
J Control Release; 2013 Mar; 166(3):268-76. PubMed ID: 23313113
[TBL] [Abstract][Full Text] [Related]
33. Communication pathways to and from the inner ear and their contributions to drug delivery.
Salt AN; Hirose K
Hear Res; 2018 May; 362():25-37. PubMed ID: 29277248
[TBL] [Abstract][Full Text] [Related]
34. Characterization of silicone pressure-sensitive adhesive episcleral implant for drug delivery.
Wen H; Li SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):107-115. PubMed ID: 25923417
[TBL] [Abstract][Full Text] [Related]
35. [Quantitative interpretation of dexamethasone pharmacokinetics in human inner ear perilymph using computer simulations].
Liu H; Dong M
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Nov; 24(22):1040-3. PubMed ID: 21322932
[TBL] [Abstract][Full Text] [Related]
36. Ototoxicity of neomycin and its penetration through the round window membrane into the perilymph.
Harada T; Iwamori M; Nagai Y; Nomura Y
Ann Otol Rhinol Laryngol; 1986; 95(4 Pt 1):404-8. PubMed ID: 3740717
[TBL] [Abstract][Full Text] [Related]
37. Drug delivery to the inner ear: strategies and their therapeutic implications for sensorineural hearing loss.
Rivera T; Sanz L; Camarero G; Varela-Nieto I
Curr Drug Deliv; 2012 May; 9(3):231-42. PubMed ID: 22283653
[TBL] [Abstract][Full Text] [Related]
38. Intracochlear PLGA based implants for dexamethasone release: Challenges and solutions.
Lehner E; Gündel D; Liebau A; Plontke S; Mäder K
Int J Pharm X; 2019 Dec; 1():100015. PubMed ID: 31517280
[TBL] [Abstract][Full Text] [Related]
39. A comparison of systemic and local dexamethasone administration: From perilymph/cochlea concentration to cochlear distribution.
Wang Y; Han L; Diao T; Jing Y; Wang L; Zheng H; Ma X; Qi J; Yu L
Hear Res; 2018 Dec; 370():1-10. PubMed ID: 30223171
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in therapeutics and drug delivery for the treatment of inner ear diseases: a patent review (2011-2015).
Nguyen K; Kempfle JS; Jung DH; McKenna CE
Expert Opin Ther Pat; 2017 Feb; 27(2):191-202. PubMed ID: 27855527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
